SG11202001553UA - Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases - Google Patents
Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseasesInfo
- Publication number
- SG11202001553UA SG11202001553UA SG11202001553UA SG11202001553UA SG11202001553UA SG 11202001553U A SG11202001553U A SG 11202001553UA SG 11202001553U A SG11202001553U A SG 11202001553UA SG 11202001553U A SG11202001553U A SG 11202001553UA SG 11202001553U A SG11202001553U A SG 11202001553UA
- Authority
- SG
- Singapore
- Prior art keywords
- bcl
- inhibitors
- treatment
- condensed heterocyclic
- neoplastic diseases
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
- G01N21/763—Bioluminescence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plasma & Fusion (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549081P | 2017-08-23 | 2017-08-23 | |
| US201862615007P | 2018-01-09 | 2018-01-09 | |
| PCT/US2018/047411 WO2019040550A1 (en) | 2017-08-23 | 2018-08-22 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001553UA true SG11202001553UA (en) | 2020-03-30 |
Family
ID=63490700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001553UA SG11202001553UA (en) | 2017-08-23 | 2018-08-22 | Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US11365206B2 (es) |
| EP (3) | EP3672975B1 (es) |
| JP (2) | JP7467332B2 (es) |
| KR (2) | KR20200092308A (es) |
| CN (4) | CN116621860A (es) |
| AU (2) | AU2018321496B2 (es) |
| CA (2) | CA3073446A1 (es) |
| DK (2) | DK3672976T3 (es) |
| ES (1) | ES2948287T3 (es) |
| FI (2) | FI3672975T3 (es) |
| IL (1) | IL272762B2 (es) |
| MX (2) | MX2020002032A (es) |
| SG (1) | SG11202001553UA (es) |
| WO (2) | WO2019040573A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3672976T3 (da) | 2017-08-23 | 2024-03-04 | Guangzhou Lupeng Pharmaceutical Company Ltd | Bcl-2-hæmmere |
| WO2020041405A1 (en) | 2018-08-22 | 2020-02-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US20220073513A1 (en) | 2018-12-29 | 2022-03-10 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| US20220372042A1 (en) | 2019-10-03 | 2022-11-24 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021083135A1 (en) * | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| AU2021228622A1 (en) | 2020-02-24 | 2022-10-13 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Hot melt extruded solid dispersions containing a BCL2 inhibitor |
| US20240166646A1 (en) | 2020-12-22 | 2024-05-23 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| CN113694059B (zh) * | 2021-03-24 | 2023-09-26 | 浙江大学 | Nl101在制备治疗急性、慢性排斥反应药物中的应用 |
| WO2023121713A1 (en) * | 2021-12-20 | 2023-06-29 | New Ave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2023122000A1 (en) * | 2021-12-20 | 2023-06-29 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US11964990B2 (en) | 2022-01-21 | 2024-04-23 | Abbvie Inc. | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| GB0623209D0 (en) * | 2006-11-21 | 2007-01-03 | F2G Ltd | Antifungal agents |
| WO2009036035A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| NZ585085A (en) | 2007-11-16 | 2012-08-31 | Abbott Lab | Method of treating arthritis using arylsulfonamide compounds |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| PT2376480T (pt) | 2008-12-05 | 2016-10-26 | Abbvie Inc | Derivados de sulfonamida como agentes indutores de apoptose seletivos de bcl-2 para o tratamento do cancro e de doenças imunes |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN109966294A (zh) | 2009-05-26 | 2019-07-05 | 艾伯维爱尔兰无限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| JP5743482B2 (ja) | 2010-10-15 | 2015-07-01 | 株式会社アルファ | エスカッション部材のハンドルベースへの連結方法 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| US20120277210A1 (en) | 2010-10-29 | 2012-11-01 | Abbott Laboratories | Solid dispersions containing an apoptosis-inducing agent |
| NZ610151A (en) | 2010-11-23 | 2015-06-26 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
| WO2014094357A1 (en) * | 2012-12-21 | 2014-06-26 | Abbvie Inc. | Heterocyclic nuclear hormone receptor modulators |
| EP3293185A1 (en) | 2013-03-13 | 2018-03-14 | AbbVie Inc. | Processes for the preparation of an apoptosis-inducing agent |
| WO2015043492A1 (en) * | 2013-09-26 | 2015-04-02 | Sunshine Lake Pharma Co., Ltd. | Substituted urea derivatives and uses thereof in medicine |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2018127130A1 (en) | 2017-01-07 | 2018-07-12 | Shanghai Fochon Pharmaceutical Co., Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| EP3612531B1 (en) | 2017-04-18 | 2022-08-24 | Shanghai Fochon Pharmaceutical Co., Ltd. | Apoptosis-inducing agents |
| DK3672976T3 (da) | 2017-08-23 | 2024-03-04 | Guangzhou Lupeng Pharmaceutical Company Ltd | Bcl-2-hæmmere |
| WO2020041405A1 (en) | 2018-08-22 | 2020-02-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US20220073513A1 (en) | 2018-12-29 | 2022-03-10 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
-
2018
- 2018-08-22 DK DK18765259.9T patent/DK3672976T3/da active
- 2018-08-22 DK DK18765254.0T patent/DK3672975T3/da active
- 2018-08-22 IL IL272762A patent/IL272762B2/en unknown
- 2018-08-22 EP EP18765254.0A patent/EP3672975B1/en active Active
- 2018-08-22 KR KR1020207008178A patent/KR20200092308A/ko active IP Right Grant
- 2018-08-22 WO PCT/US2018/047444 patent/WO2019040573A1/en unknown
- 2018-08-22 MX MX2020002032A patent/MX2020002032A/es unknown
- 2018-08-22 FI FIEP18765254.0T patent/FI3672975T3/fi active
- 2018-08-22 WO PCT/US2018/047411 patent/WO2019040550A1/en unknown
- 2018-08-22 KR KR1020207008179A patent/KR20200090738A/ko active IP Right Grant
- 2018-08-22 AU AU2018321496A patent/AU2018321496B2/en active Active
- 2018-08-22 CN CN202310439771.XA patent/CN116621860A/zh active Pending
- 2018-08-22 FI FIEP18765259.9T patent/FI3672976T3/fi active
- 2018-08-22 CA CA3073446A patent/CA3073446A1/en active Pending
- 2018-08-22 JP JP2020510610A patent/JP7467332B2/ja active Active
- 2018-08-22 JP JP2020510576A patent/JP7467331B2/ja active Active
- 2018-08-22 CA CA3073445A patent/CA3073445A1/en active Pending
- 2018-08-22 ES ES18765254T patent/ES2948287T3/es active Active
- 2018-08-22 EP EP23167453.2A patent/EP4227311A1/en active Pending
- 2018-08-22 CN CN201880067225.5A patent/CN111511748B/zh active Active
- 2018-08-22 CN CN201880067185.4A patent/CN111448198B/zh active Active
- 2018-08-22 EP EP18765259.9A patent/EP3672976B1/en active Active
- 2018-08-22 AU AU2018322059A patent/AU2018322059B2/en active Active
- 2018-08-22 MX MX2020002033A patent/MX2020002033A/es unknown
- 2018-08-22 SG SG11202001553UA patent/SG11202001553UA/en unknown
- 2018-08-22 CN CN202310267471.8A patent/CN116425771A/zh active Pending
-
2020
- 2020-02-20 US US16/795,720 patent/US11365206B2/en active Active
- 2020-02-20 US US16/795,884 patent/US11279711B2/en active Active
-
2022
- 2022-03-18 US US17/698,289 patent/US11680072B2/en active Active
- 2022-06-15 US US17/840,957 patent/US11993610B2/en active Active
-
2023
- 2023-05-03 US US18/142,842 patent/US20230271979A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272762A (en) | Compressed heterocyclics as BCL-2 inhibitors for the treatment of neoplastic diseases | |
| HK1247922A1 (zh) | 用於治療癌症的吲哚胺2，3-雙加氧酶抑制劑 | |
| IL253945B (en) | kdm1a inhibitors to treat the disease | |
| PH12016502179A1 (en) | Inhibitors of lysine specific demethylase-1 | |
| EP3618829C0 (en) | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-ASSOCIATED DISORDERS | |
| IL272444A (en) | Compounds, their salts and methods for treating diseases | |
| IL261015B (en) | History of methylamine as lysyl oxidase inhibitors for cancer treatment | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| PL3634417T3 (pl) | Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem | |
| IL275496A (en) | Glycolate oxidase inhibitors to treat the disease | |
| IL254266B (en) | Glucosylceramide synthase inhibitors for the treatment of diseases | |
| IL272601A (en) | Pharmaceutical preparations for the treatment of ophthalmic conditions | |
| PT3578562T (pt) | Derivados de amida de l-valinato benzoxaborole para o tratamento de doenças parasitárias | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| IL249502B (en) | New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins | |
| GB201506654D0 (en) | Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia | |
| HK1249044A1 (zh) | 用於治療或預防神經退行性疾病的槍刀藥素氧化物、其衍生物、相關化合物和激動劑 | |
| EP3371154A4 (en) | HETEROCYCLIC DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS |